Azurity Pharmaceuticals
Latest round
- Series A
Last raised
- Sep 2014
Total raised
- $4M
Investors
- 1
About Azurity Pharmaceuticals
Based in the US, Azurity Pharmaceuticals, Inc.Azurity Pharmaceuticals, Inc. specializes in creating specialty pharmaceuticals aimed at underserved patient demographics. Founded in 1998 in Woburn, US, the company underwent a rebranding when Silvergate Pharmaceuticals, Inc. was acquired by CutisPharma, Inc. in June 2019.Azurity Pharmaceuticals specializes in the development and commercialization of innovative medicines aimed at addressing the needs of overlooked patient populations. Their diversified product portfolio includes over 50 medications across 10 different dosage forms and key therapeutic areas such as cardiovascular health, oncology, immunology, and respiratory conditions. A notable product in their lineup is Javadin™ (clonidine hydrochloride) oral solution, which is the only FDA-approved immediate-release liquid formulation for treating hypertension in adults, released in October 2025.Revenue generation for Azurity Pharmaceuticals primarily occurs through the sale of its specialty pharmaceuticals to healthcare providers and distributors. The company engages in direct sales and partnership agreements, such as the exclusive distribution deal with ACA Pharma for Feraheme® (ferumoxytol injection) in the Greater Bay Area and Singapore, enhancing its market reach. Transactions are typically structured as B2B agreements, with healthcare facilities purchasing medications to treat their patients. Flagship products like Javadin™ and Feraheme® represent key revenue streams, as they fulfill significant treatment needs within their respective therapeutic areas.Azurity Pharmaceuticals plans to further its growth by developing new products, including the upcoming Javadin™ oral solution, expected to enhance treatment options for hypertension in adults. The company aims to expand its market presence in Asia, specifically targeting regions such as Hong Kong and Mainland China, by 2026.
Who invested in Azurity Pharmaceuticals
1 investor across 2 rounds
See all investors in Azurity Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Azurity Pharmaceuticals
Who invested in Azurity Pharmaceuticals?
Azurity Pharmaceuticals has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Azurity Pharmaceuticals raised?
Azurity Pharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Azurity Pharmaceuticals last raise money?
Azurity Pharmaceuticals's most recent round on record is a Series A, in Sep 2014.
What does Azurity Pharmaceuticals do?
Based in the US, Azurity Pharmaceuticals, Inc.
Where is Azurity Pharmaceuticals headquartered?
Azurity Pharmaceuticals is headquartered in Woburn, US.
Which VCs invest in companies like Azurity Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Azurity Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Azurity Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.